Prostaglandin production in chronic progressive multiple sclerosis

Judith A. Aberg, Laurence M. Demers, Paula J. Romano, Richard B. Tenser

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Peripheral blood monocytes have been implicated in the immune reactions that accompany demyelination in patients with multiple sclerosis (MS). We measured prostaglandin E2 (PGE2) and thromboxane B2 (TxB2) release from peripheral monocytes exposed in vitro to complement. Our studies suggest that there is a significantly higher production of PGE2 in monocytes from patients with chronic progressive MS than in those with exacerbation or remitting MS and healthy controls. No significant differences in TxB2release were noted between the three groups.

Original languageEnglish (US)
Pages (from-to)246-250
Number of pages5
JournalJournal of Clinical Laboratory Analysis
Volume4
Issue number4
DOIs
StatePublished - 1990

Fingerprint

Chronic Progressive Multiple Sclerosis
Dinoprostone
Prostaglandins
Monocytes
Antigen-antibody reactions
Thromboxane B2
Multiple Sclerosis
Blood
Demyelinating Diseases

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Clinical Biochemistry
  • Medical Laboratory Technology
  • Biochemistry, medical
  • Microbiology (medical)

Cite this

Aberg, Judith A. ; Demers, Laurence M. ; Romano, Paula J. ; Tenser, Richard B. / Prostaglandin production in chronic progressive multiple sclerosis. In: Journal of Clinical Laboratory Analysis. 1990 ; Vol. 4, No. 4. pp. 246-250.
@article{af4dca99bc49414f92ed312845362f10,
title = "Prostaglandin production in chronic progressive multiple sclerosis",
abstract = "Peripheral blood monocytes have been implicated in the immune reactions that accompany demyelination in patients with multiple sclerosis (MS). We measured prostaglandin E2 (PGE2) and thromboxane B2 (TxB2) release from peripheral monocytes exposed in vitro to complement. Our studies suggest that there is a significantly higher production of PGE2 in monocytes from patients with chronic progressive MS than in those with exacerbation or remitting MS and healthy controls. No significant differences in TxB2release were noted between the three groups.",
author = "Aberg, {Judith A.} and Demers, {Laurence M.} and Romano, {Paula J.} and Tenser, {Richard B.}",
year = "1990",
doi = "10.1002/jcla.1860040403",
language = "English (US)",
volume = "4",
pages = "246--250",
journal = "Journal of Clinical Laboratory Analysis",
issn = "0887-8013",
publisher = "Wiley-Liss Inc.",
number = "4",

}

Prostaglandin production in chronic progressive multiple sclerosis. / Aberg, Judith A.; Demers, Laurence M.; Romano, Paula J.; Tenser, Richard B.

In: Journal of Clinical Laboratory Analysis, Vol. 4, No. 4, 1990, p. 246-250.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prostaglandin production in chronic progressive multiple sclerosis

AU - Aberg, Judith A.

AU - Demers, Laurence M.

AU - Romano, Paula J.

AU - Tenser, Richard B.

PY - 1990

Y1 - 1990

N2 - Peripheral blood monocytes have been implicated in the immune reactions that accompany demyelination in patients with multiple sclerosis (MS). We measured prostaglandin E2 (PGE2) and thromboxane B2 (TxB2) release from peripheral monocytes exposed in vitro to complement. Our studies suggest that there is a significantly higher production of PGE2 in monocytes from patients with chronic progressive MS than in those with exacerbation or remitting MS and healthy controls. No significant differences in TxB2release were noted between the three groups.

AB - Peripheral blood monocytes have been implicated in the immune reactions that accompany demyelination in patients with multiple sclerosis (MS). We measured prostaglandin E2 (PGE2) and thromboxane B2 (TxB2) release from peripheral monocytes exposed in vitro to complement. Our studies suggest that there is a significantly higher production of PGE2 in monocytes from patients with chronic progressive MS than in those with exacerbation or remitting MS and healthy controls. No significant differences in TxB2release were noted between the three groups.

UR - http://www.scopus.com/inward/record.url?scp=0025127761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025127761&partnerID=8YFLogxK

U2 - 10.1002/jcla.1860040403

DO - 10.1002/jcla.1860040403

M3 - Article

C2 - 2391581

AN - SCOPUS:0025127761

VL - 4

SP - 246

EP - 250

JO - Journal of Clinical Laboratory Analysis

JF - Journal of Clinical Laboratory Analysis

SN - 0887-8013

IS - 4

ER -